Legend Biotech Corp
No SEC Form 4 filings for $LEGN in the last 30 days.
See all $LEGN insider activity →Morgan Stanley raised its price target on Legend Biotech (LEGN) to $49 from $48 and maintained an Overweight rating, according to TipRanks. The note highlights continued support from CARVYKTI momentum and valuation, with an unchanged $65 target cited in related coverage.
Legend Biotech Corporation disclosed that certain restricted share units held by executive officers, directors, and a shareholder are under a 60-day lock-up ending 16 Aug 2026, starting 17 Jun 2026. After the lock-up, about 175 million ordinary shares (including ADSs) may enter public sale; total shares outstanding are 386,879,583.
Fierce Pharma Asia reports Legend Biotech’s first profitable quarter, with $63M adjusted net income for the three months ended June, as it expands Carvykti. Taiho and Cullinan’s zipalertinib posted a positive phase 3 in EGFR exon 20-mutated NSCLC. WuXi AppTec won a preliminary injunction against a U.S. DoD blacklist designation.
Over the past 7 days, alphai's AI scored 11 news stories mentioning LEGN (Legend Biotech Corp). Coverage has skewed bullish: 7 bullish, 2 neutral, and 2 bearish.
Recent LEGN coverage spans earnings, financial news and corporate actions.
The analyst target hike is a near-term sentiment tailwind, but it is not a new fundamental disclosure beyond the rating change.
Lock-up expiration increases near-term float and potential sell pressure, which can pressure the stock around the release window.
First profitability and management commentary can re-rate near-term cash runway and commercial momentum for Carvykti.
The call provides fresh operating leverage details plus a sequential gross-margin headwind for Q3, alongside continued CARVYKTI growth and cash build.
Downgrade may weigh on sentiment, but absence of a target change reduces the immediacy of the signal.
alphai scores every news story that mentions LEGN with an AI model for sentiment and relevance, and aggregates insider trades from Legend Biotech Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley raised its price target on Legend Biotech (LEGN) to $49 from $48 and maintained an Overweight rating, according to TipRanks. The note highlights continued support from CARVYKTI momentum and valuation, with an unchanged $65 target cited in related coverage.
1 min readLegend Biotech Corporation disclosed that certain restricted share units held by executive officers, directors, and a shareholder are under a 60-day lock-up ending 16 Aug 2026, starting 17 Jun 2026. After the lock-up, about 175 million ordinary shares (including ADSs) may enter public sale; total shares outstanding are 386,879,583.
2 min readFierce Pharma Asia reports Legend Biotech’s first profitable quarter, with $63M adjusted net income for the three months ended June, as it expands Carvykti. Taiho and Cullinan’s zipalertinib posted a positive phase 3 in EGFR exon 20-mutated NSCLC. WuXi AppTec won a preliminary injunction against a U.S. DoD blacklist designation.
7 min readLegend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.
6 min read24/7 Wall St. lists Wednesday analyst research calls. Upgrades include Hilton (HLT) to Buy with a $365 target, Intuitive Surgical (ISRG) to Outperform with a $500 target, Merck (MRK) to Outperform with a $143 target, and Okta (OKTA) to Outperform with a $170 target. Downgrades include The Gap (GAP) to Hold, and Novo Nordisk (NVO) to Hold. Initiations cover Genmab (GMAB) and Marriott (MAR).
6 min readLegend Biotech (LEGN) fell 2.4% in pre-open trading after a Q2 2026 earnings beat. Adjusted EPS was $0.16 versus $0.07 consensus, and revenue was $387.5 million versus $362.81 million expected, with the company reporting its first quarter of company-wide profitability. Oppenheimer downgraded it to Perform and cut its price target to $40 from $75, citing competitive pressure on CARVYKTI and limited near-term catalysts.
4 min readLegend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657 million, up 50% YoY. Total revenue was $387.5 million, up 52% YoY, with adjusted net income of $63.1 million ($0.16/share). Cash was $965 million. Q3 gross margin guidance was in the lower 50% range.
7 min readLegend Biotech (LEGN) said it reached its first quarter of company-wide profitability, citing improved operating leverage. The company reported 50% year-over-year growth in CARVYKTI sales and highlighted progress in its pipeline, including expansion into earlier lines and new markets. It also noted a strong cash position and an equity raise supporting continued development, according to its Q2 2026 audio transcript.
1 min readLegend Biotech (NASDAQ:LEGN) shares rose about 6% after Q2 results. Revenue was $387.5M, up 52% and above the $362.81M estimate. Adjusted EPS was $0.16, more than double consensus. CARVYKTI net sales were $657M (+50%), and the company reported its first profitable quarter, with cash about $965M and no long-term debt.
6 min readLegend Biotech shares rose after the company reported a second-quarter profit and higher revenue. Net income was $33.2 million, or $0.09 per share, versus a year-ago loss of $125.4 million, or $0.34. Revenue increased to $387.5 million from $255.1 million, driven by Carvykti sales. Analysts expected $356 million.
3 min read
